Outlook Therapeutics Inc (OTLK)

[H2R]

2024 OTLK Anticipated Milestones

FDA response on NORSE EIGHT Special Protocol Assessment (SPA) in early February 2024;

Commencement of NORSE EIGHT expected in first calendar quarter of 2024;

MAA decision date in the EU for ONS-5010 expected targeted for first half of 2024;

Completion of NORSE EIGHT in the U.S. anticipated in 2024; and

Resubmission of the ONS-5010 BLA expected by the end of calendar year 2024.

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-reports-financial-results-fiscal-year-2023

Best of luck with your investments!